Contrasting Genscript Biotech (OTCMKTS:GNNSF) & Hyperion DeFi (NASDAQ:HYPD)

Genscript Biotech (OTCMKTS:GNNSF) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Profitability

This table compares Genscript Biotech and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genscript Biotech	N/A	N/A	N/A
Hyperion DeFi	N/A	-129.97%	-92.39%

Analyst Ratings

This is a summary of current recommendations and price targets for Genscript Biotech and Hyperion DeFi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genscript Biotech	0	0	0	0	0.00
Hyperion DeFi	2	0	1	1	2.25

Hyperion DeFi has a consensus target price of $5.88, suggesting a potential upside of 64.57%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than Genscript Biotech.

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Genscript Biotech and Hyperion DeFi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genscript Biotech	N/A	N/A	N/A	N/A	N/A
Hyperion DeFi	$810,000.00	50.20	-$45.31 million	($11.80)	-0.30

Genscript Biotech has higher earnings, but lower revenue than Hyperion DeFi.

Summary

Hyperion DeFi beats Genscript Biotech on 7 of the 9 factors compared between the two stocks.

About Genscript Biotech

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.